Neopath Diagnostics And Research Centre Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-12-2024
- Paid Up Capital ₹ 0.10 M
as on 24-12-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.98 M
as on 24-12-2024
- Revenue %
(FY 2020)
- Profit 381.11%
(FY 2020)
- Ebitda 127.68%
(FY 2020)
- Net Worth 37.92%
(FY 2020)
- Total Assets -0.62%
(FY 2020)
About Neopath Diagnostics And Research Centre
The Company is engaged in the Service Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.98 M.
Jitesh Patel and Amitaben Patel serve as directors at the Company.
- CIN/LLPIN
U93000GJ2017PTC097770
- Company No.
097770
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neopath Diagnostics And Research Centre?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitesh Patel  | Director | 06-Jun-2017 | Current |
| Amitaben Patel | Director | 06-Jun-2017 | Current |
Financial Performance of Neopath Diagnostics And Research Centre.
Neopath Diagnostics And Research Centre Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 381.11% increase in profit. The company's net worth Soared by an impressive increase of 37.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neopath Diagnostics And Research Centre?
Unlock access to Neopath Diagnostics And Research Centre's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Hreedrak Bioscience Private LimitedActive 7 months 7 days
Jitesh Patel and Amitaben Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Sutex Co-Operative Bank Ltd. Creation Date: 11 May 2021 | ₹2.80 M | Open |
Others Creation Date: 15 Feb 2018 | ₹1.19 M | Open |
How Many Employees Work at Neopath Diagnostics And Research Centre?
Unlock and access historical data on people associated with Neopath Diagnostics And Research Centre, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neopath Diagnostics And Research Centre, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neopath Diagnostics And Research Centre's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
